Literature DB >> 11298185

Metabolic cardiomyopathies.

B Guertl1, C Noehammer, G Hoefler.   

Abstract

The energy needed by cardiac muscle to maintain proper function is supplied by adenosine Ariphosphate primarily (ATP) production through breakdown of fatty acids. Metabolic cardiomyopathies can be caused by disturbances in metabolism, for example diabetes mellitus, hypertrophy and heart failure or alcoholic cardiomyopathy. Deficiency in enzymes of the mitochondrial beta-oxidation show a varying degree of cardiac manifestation. Aberrations of mitochondrial DNA lead to a wide variety of cardiac disorders, without any obvious correlation between genotype and phenotype. A completely different pathogenetic model comprises cardiac manifestation of systemic metabolic diseases caused by deficiencies of various enzymes in a variety of metabolic pathways. Examples of these disorders are glycogen storage diseases (e.g. glycogenosis type II and III), lysosomal storage diseases (e.g. Niemann-Pick disease, Gaucher disease, I-cell disease, various types of mucopolysaccharidoses, GM1 gangliosidosis, galactosialidosis, carbohydrate-deficient glycoprotein syndromes and Sandhoff's disease). There are some systemic diseases which can also affect the heart, for example triosephosphate isomerase deficiency, hereditary haemochromatosis, CD 36 defect or propionic acidaemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11298185      PMCID: PMC2517748          DOI: 10.1046/j.1365-2613.2000.00186.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  198 in total

1.  I-cell disease: clinical studies of 21 Japanese cases.

Authors:  S Okada; M Owada; T Sakiyama; T Yutaka; M Ogawa
Journal:  Clin Genet       Date:  1985-09       Impact factor: 4.438

2.  Calcification of the ascending aorta and aortic and mitral valves in Gaucher's disease.

Authors:  A Casta; K Hayden; W J Wolf
Journal:  Am J Cardiol       Date:  1984-12-01       Impact factor: 2.778

3.  Deficiency of medium chain fatty acylcoenzyme A dehydrogenase presenting as the sudden infant death syndrome.

Authors:  A J Howat; M J Bennett; S Variend; L Shaw
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-31

4.  Inhibition of sarcolemmal Na+-K+-ATPase by palmitoyl carnitine: potentiation by propranolol.

Authors:  J H Kramer; W B Weglicki
Journal:  Am J Physiol       Date:  1985-01

5.  Effects of fatty acids on Na/Ca exchange in cardiac sarcolemmal membranes.

Authors:  T F Ashavaid; R A Colvin; F C Messineo; T MacAlister; A M Katz
Journal:  J Mol Cell Cardiol       Date:  1985-09       Impact factor: 5.000

6.  An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes.

Authors:  P G Barth; H R Scholte; J A Berden; J M Van der Klei-Van Moorsel; I E Luyt-Houwen; E T Van 't Veer-Korthof; J J Van der Harten; M A Sobotka-Plojhar
Journal:  J Neurol Sci       Date:  1983-12       Impact factor: 3.181

7.  Lipolysis in isolated myocardial cells from diabetic rat hearts.

Authors:  K A Kenno; D L Severson
Journal:  Am J Physiol       Date:  1985-11

8.  Presence of nonoxidative ethanol metabolism in human organs commonly damaged by ethanol abuse.

Authors:  E A Laposata; L G Lange
Journal:  Science       Date:  1986-01-31       Impact factor: 47.728

9.  The effects of acute and chronic diabetes on myocardial metabolism in rats.

Authors:  V Chen; C D Ianuzzo; B C Fong; J J Spitzer
Journal:  Diabetes       Date:  1984-11       Impact factor: 9.461

10.  Lipoprotein composition as a component in the lipoprotein clearance defect in experimental diabetes.

Authors:  P O'Looney; D Irwin; P Briscoe; G V Vahouny
Journal:  J Biol Chem       Date:  1985-01-10       Impact factor: 5.157

View more
  34 in total

Review 1.  Correction of dysfunctional fatty acid metabolism using peroxisome proliferator activated receptor gamma agonists.

Authors:  Nicholas D Oakes; Bengt Ljung; Germán Camejo
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 2.  The heart in Anderson-Fabry disease and other lysosomal storage disorders.

Authors:  Ales Linhart; Perry M Elliott
Journal:  Heart       Date:  2007-04       Impact factor: 5.994

Review 3.  Lysosomal storage disorders in the newborn.

Authors:  Orna Staretz-Chacham; Tess C Lang; Mary E LaMarca; Donna Krasnewich; Ellen Sidransky
Journal:  Pediatrics       Date:  2009-04       Impact factor: 7.124

Review 4.  Metabolic remodeling in early development and cardiomyocyte maturation.

Authors:  Rebecca Ellen Kreipke; Yuliang Wang; Jason Wayne Miklas; Julie Mathieu; Hannele Ruohola-Baker
Journal:  Semin Cell Dev Biol       Date:  2016-02-18       Impact factor: 7.727

5.  Metabolomics-assisted proteomics identifies succinylation and SIRT5 as important regulators of cardiac function.

Authors:  Sushabhan Sadhukhan; Xiaojing Liu; Dongryeol Ryu; Ornella D Nelson; John A Stupinski; Zhi Li; Wei Chen; Sheng Zhang; Robert S Weiss; Jason W Locasale; Johan Auwerx; Hening Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-05       Impact factor: 11.205

Review 6.  Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.

Authors:  Nikita Ikon; Robert O Ryan
Journal:  Lipids       Date:  2017-01-09       Impact factor: 1.880

Review 7.  The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.

Authors:  Iain P Hargreaves; Andrew J Duncan; Simon J R Heales; John M Land
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

8.  Role of proteases in the pathophysiology of cardiac disease.

Authors:  Raja B Singh; Sucheta P Dandekar; Vijayan Elimban; Suresh K Gupta; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

Review 9.  Genetic determinants of cardiac hypertrophy.

Authors:  Ali J Marian
Journal:  Curr Opin Cardiol       Date:  2008-05       Impact factor: 2.161

10.  Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha ) and mitochondrial function by MEF2 and HDAC5.

Authors:  Michael P Czubryt; John McAnally; Glenn I Fishman; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.